Kuros to Begin Fibrin-PTH Clinical Trial in Spinal Fusion

Kuros Biosciences gained FDA approval for its Investigational New Drug (IND) application to initiate a Phase IIA clinical trial to evaluate Fibrin-PTH orthobiologic material (KUR-113) in single level transforaminal lumbar interbody fusion to treat degenerative disc disease, with autograft as comparator.

This IND application is considered to be...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us